Evidence mapPaperPMID 35544273Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2022

Urea levels and cardiovascular disease in patients with chronic kidney disease.

Solène M Laville, Aymeric Couturier, Oriane Lambert, Marie Metzger, Nicolas Mansencal, Christian Jacquelinet, Maurice Laville, Luc Frimat, Denis Fouque, Christian Combe and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Dietary Protein Intake in CKD: Quantity and Quality.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 2 countries.

Solène M LavilleDepartment of Clinical Pharmacology, Amiens University Hospital, Amiens, France.ORCID 0000-0002-0214-5567
Aymeric CouturierDepartment of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, Paris, France.
Oriane LambertCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM UMRS, 1018 Villejuif, France.
Marie MetzgerCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM UMRS, 1018 Villejuif, France.
Nicolas MansencalCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM UMRS, 1018 Villejuif, France.ORCID 0000-0001-5500-1535
Christian JacquelinetBiomedecine Agency, Saint Denis La Plaine, France.
Maurice LavilleUniversité de Lyon, CarMeN INSERM 1060, Lyon, France.
Luc FrimatNephrology Department, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.
Denis FouqueUniversité de Lyon, CarMeN INSERM 1060, Lyon, France.
Christian CombeService de Néphrologie Transplantation Dialyse Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.ORCID 0000-0002-0360-573X
Bruce M RobinsonArbor Research Collaborative for Health, Ann Arbor MI, USA.
Bénédicte StengelCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM UMRS, 1018 Villejuif, France.
Sophie LiabeufDepartment of Clinical Pharmacology, Amiens University Hospital, Amiens, France.ORCID 0000-0001-5384-9006
Ziad A MassyDepartment of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, Paris, France.
CKD-REIN study collaborators
Inserm · FRUniversité Claude Bernard Lyon 1 · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire Amiens-Picardie · FRInterdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes – Région Est · FRCentre de recherche en Epidémiologie et Santé des Populations · FRArbor Research Collaborative for Health · USUniversité de Bordeaux · FRAgence de la Biomédecine · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated serum urea levels are common in moderate-to-advanced CKD. Several studies have shown that urea is a direct and indirect uremic toxin, especially with regard to cardiovascular disease. We sought to determine whether serum urea levels are associated with adverse cardiovascular events and death before renal replacement therapy (RRT) in patients with CKD.

methodsCKD-REIN is a prospective cohort of CKD nephrology outpatients not receiving maintenance dialysis. The 2507 patients included in the analysis were divided into three groups according to the baseline serum urea level (T1 < 10.5, T2:10.5 to 15.1, and T3 ≥ 15.1 mmol/L). Cox proportional hazard models were used to estimate hazard ratios (HRs) for first atheromatous or nonatheromatous cardiovascular (CV) events, and all-cause mortality before RRT. The models were adjusted for baseline comorbidities, laboratory data, and medications.

findingsOf the 2507 included patients (median [interquartile range (IQR)] age: 69[61-77]; mean (standard deviation) eGFR 33.5(11.6) mL/min/1.73 m²), 54% had a history of cardiovascular disease. After multiple adjustments for cardiovascular risk factors (including eGFR), patients in T3 had a higher risk of atheromatous and nonatheromatous cardiovascular events than patient in T1 (n events = 451, HR[95%CI]: 1.93[1.39-2.69]). The adjusted HRs for death before RRT (n events = 407) were 1.31[0.97; 1.76] and 1.73[1.22; 2.45] for patients T2 and those in T3, respectively.

interpretationOur data suggested that urea is a predictor of cardiovascular outcomes beyond CV risk factors including eGFR.

Indexed as

cardiovascular diseasechronic kidney diseaseureauremic toxin

Identifiers

PMID35544273
PMCPMC9869852
OpenAlexW4213424664

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.